Neuregulin-1 Induces Cardiac Hypertrophy and Impairs Cardiac Performance in Post-Myocardial Infarction Rats

Circulation. 2020 Sep 29;142(13):1308-1311. doi: 10.1161/CIRCULATIONAHA.119.044313. Epub 2020 Sep 28.

Authors

Magdalena Zurek^#¹, Edvin Johansson^{1

2}, Malin Palmer³, Tamsin Albery³, Karin Johansson³, Katarina Rydén-Markinhutha³, Qing-Dong Wang^#³

Affiliations

¹ Imaging and AI, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.Z., E.J.).
² Antaros Medical, Mölndal, Sweden (E.J.).
³ Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (M.P., T.A., K.J., K.R.-M., Q.-D.W.).

^# Contributed equally.

PMID: 32986480
DOI: 10.1161/CIRCULATIONAHA.119.044313

No abstract available

Keywords: hypertrophy; neuregulins; ventricular dysfunction, left.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Cardiomegaly* / etiology
Cardiomegaly* / metabolism
Cardiomegaly* / physiopathology
Humans
Myocardial Infarction* / complications
Myocardial Infarction* / metabolism
Myocardial Infarction* / physiopathology
Neuregulin-1* / adverse effects
Neuregulin-1* / pharmacology
Rats
Stroke Volume / drug effects*

Substances

Neuregulin-1
Nrg1 protein, rat